Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of...
Hovione has issued a bond of $50 million US dollars maturing in 2033. (Logo: https://mma.prnewswire.com/media/813604/Hovione_Logo.jpg ) The bond was...
Hovione announces plan to increase production capacity in oral dosage forms in Portugal, to strengthen the integrated offering. New commercial scale...
Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey, with the aim to: increase...
Hovione a annoncé aujourd'hui une récente expansion de ses capacités et des projets futurs pour ses sites au Portugal, en Irlande et dans le New...
Hovione gab heute seine jüngsten Kapazitätserweiterungs- und zukünftigen Pläne an seinen Standorten in Portugal, Irland und New Jersey, USA bekannt...
Hovione announced today that in the last year their manufacturing facilities were the object of eight inspections, performed by different Health...
Hovione announces that it has concluded the sale of all of the share capital of iMAX Diagnostic Imaging Holding Limited. For Hovione this sale marks...
Hovione announced today enrollment of the first patient in MARS (Minocycline Against Rosacea Study), a Phase 2 clinical study of topical minocycline...
Hovione kündigt heute die Ernennung von Herrn Frédéric Kahn zum Vice President Marketing and Sales mit Wirkung zum 1. September 2017 an. Herr Kahn...
Hovione a annoncé aujourd'hui la nomination de M. Frédéric Kahn au poste de vice-président du marketing et des ventes, à compter du 1er septembre...
Hovione announced today the appointment of Mr. Frédéric Kahn as Vice President Marketing and Sales, as of 1st September, 2017. Mr. Kahn was most...
Hovione gab heute den Start seiner ersten klinischen Studie bekannt. Schon bald wird Hovione mit der Rekrutierung für seine Phase-1-Studie zu HY02...
Hovione a annoncé aujourd'hui le lancement de son premier essai clinique. Hovione commencera bientôt le recrutement pour son essai clinique de phase...
Hovione today announced the launch of its first clinical trial. Hovione will soon initiate recruitment for its Phase 1 clinical trial of HY02, a...
Hovione announced today that it held on June 8th the official groundbreaking for the expansion of its New Jersey Facility in East Windsor, USA. The...
Hovione is pleased to announce the opening of its new sales and customer support office in Osaka, Japan. The new office underlines the importance of...
Hovione today announced that it plans to host and operate a commercial-scale continuous manufacturing facility as part of an agreement with Vertex...
Hovione announced today that it is investing in specialized formulation capabilities. The first step of the plan was the acquisition of a formulation ...
Hovione announced today the appointment of Ms. Kristine Senft as Vice President Sales and Marketing. Ms. Senft joined Hovione on the 1st October and...
Hovione announced today the expansion of its New Jersey facility in East Windsor, USA. This investment is part of the company's strategy to increase...
Hovione announced today the installation of a new large scale spray drying unit in Loures, Portugal. This new state-of-the-art unit is specifically...
Hovione today announced the appointment of Dr. Filipe Gaspar as Vice President of its Research and Development organization. Dr. Gaspar will lead...
Hovione today announced that the U.S. Food and Drug Administration (FDA) performed a Pre-Approval Inspection to its plant in Loures, Portugal,...
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA). This...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.